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Abstract
Background: Gastrointestinal stromal tumors (GIST) are infrequent and diagnosis and prognosis
could be troublesome. We present short and long term results of surgical resection for GIST at
the Department of Surgery, University of Insubria, during a period of 17 years.
Materials and methods: All patients' data, tumor characteristics, surgical procedure and survival
data were analyzed retrospectively. Tumors were divided in risk classes using the classification
proposed by Fletcher, based on tumor size and number of mitosis.
Results: Between 1987 and 2004, 25 patients underwent surgical resection for GIST. Stomach was
the most common site of localization. Complete resection was achieved in 88% cases, while in 12%
radical resection was not possible. The mean tumor size was 9.2 cm (1.2 – 30 cm): <5 cm diameter
in 14/25 cases (56%), 5–10 cm in 5/25 (20%) and >10 cm in 6/25 (24%). Mitotic count was <10/50
HPF in 68% (17/25) and >10/50 in 32% (8/25). Using Fletcher's classification, tumors were divided
in very low (11/25, 44%), low (4/25, 16%), intermediate (6/25, 24%) and high-risk (4/25, 16%)
groups. The 5-year overall survival was 65% and 34% respectively with a statistically significant
difference between tumors <5 cm and >10 cm in diameter and between complete and incomplete
resection. High-risk tumors had a significantly shorter survival than low or very low risk.
Conclusion: Our experience confirms that GIST's are uncommon and aggressive cancers. The
prognosis is strictly related to tumor size and number of mitosis. Although significant advances on
new chemotherapeutic regimes have been made, to date, only radical surgery offers the chance of
long-term survival.
Background
Gastrointestinal stromal tumors (GIST) are extremely
unusual neoplasm accounting for less than 1% of all gas-
trointestinal tumors, arising from the Cajal's interstitial
cells located in mesodermal tissue. They are defined as pri-
mary mesenchymal tumors, typically staining positive for
the expression of c-KIT protein [1]. Diagnosis is complex
and always requires immunohistochemical staining, since
it is based on specific ultrastructural characteristics and
positivity for specific immunophenotype markers [1,2].
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ior of GIST are depending to tumor size and mitotic
count, regardless their benign or malignant microscopic
features [3]. Fletcher et al [2] divided GIST in different
classes of risk, based on the analysis of prognostic factors
[4,5] classifying these tumors in different "risk classes".
Despite recent advances in chemotherapeutic regimens,
such as introduction of targeted therapy with inhibitors of
tyrosine kinase receptors [6], surgical resection is still con-
sidered the treatment of choice for GIST [7].
We present short and long-term results of surgical resec-
tion of patients suffering from different types of GIST over
a period of 17 years.
Materials and methods
Between 1987 and 2004, 25 patients (15 male and 10
female, mean age of 69 ± 8 years, range 34–80) underwent
surgical resection for different type of GIST. The tumors
were located in the stomach, small bowel, large bowel and
peritoneum in 10, 10, 2 and 3 patients respectively.
All patients' data, tumor characteristics, surgical proce-
dure, intra and postoperative complications, as well as fol-
low-up and survival data, was entered in a specifically
designated computer data base and was analyzed retro-
spectively.
Histopathological examination of surgical specimens was
carried out using standard hematoxylin and eosin staining
as well as specific immunohistochemical techniques
allowing the identification of tumor's grade (low, moder-
ate, and high), size, cellular pattern, stromal background,
stage and number of mitosis at high-power field (HPF).
Using the standard histological classifications [3], 9/25
(36%) tumors were considered malignant, 2/25 (8%) of
uncertain behavior (border line) and 16/25 (64%)
benign.
The mean tumor size was 9.4 cm (range 1.2 – 30 cm): <5
cm diameter in 14/25 (56%) cases, 5–10 cm in 5/25
(20%) and >10 cm in the remaining 6/25 cases (24%).
Mitotic count was low (<10/50 High-Power Field) in 68%
(17/25) of the tumors and was high (>10/50 High-Power
Field) in the remaining cases (32% 8/25).
Using the "risk of aggressive behavior" classification pro-
posed by Fletcher et al [2] (Table 1) tumors were classified
as very low (11/25, 44%), low (4/25, 16%), intermediate
(6/25, 24%) and high-risk (4/25, 16%). In the last 12
patients c-KIT analysis have been performed and all but
one have been found to be positive.
Five out of 25 patients (20%) were affected by significant
coexisting malignancy: mesocolic located tumor associ-
ated with lung cancer (one patient); adenocarcinoma of
the stomach (three patients) and, finally, cancer of the left
colon was associated to pelvic GIST (one patient). These
patients, even if both tumors were resected, were excluded
from the survival analysis.
Clinical follow-up recorded late postoperative complica-
tions, recurrence (local and distant) and actuarial survival
based on Kaplan-Meier method.
Results
All patients underwent surgical resection. Table 2
describes the surgical procedure performed in relation to
Table 1: Proposed approach for defining risk of aggressive 
behavior in GIST, by Fletcher [2]
Tumor Size (cm) Mitotic count
Very low risk < 2 cm < 5/50 HPF
Low risk 2–5 cm < 5/50 HPF
Intermediate risk < 5 cm 6–10/50 HPF
5–10 cm < 5/50 HPF
High risk > 5 cm > 5/50 HPF
> 10 cm any mitotic rate
any size > 10/50 HPF
Table 2: Surgical procedures for resection of GIST
Site (n) Procedure Complete/incomplete
Stomach (10) Local resection = 6 (60%)
Partial gastrectomy = 3 (30%)




Small bowel (10) Local resection = 4 (40%)
Small bowel resection = 6 (60%)
Macroscopically complete
Macroscopically complete
Peritoneum (3) Local resection = 1 (33.3%)
Bulky excision = 2 (66.7%)
Macroscopically complete
Incomplete
Colon (2) Local resection = 1 (50%)
Left colon resection + pelvic metastasectomy = 1 (50%)
Macroscopically complete
IncompletePage 2 of 5
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was achieved in 22/25 (88%) cases and in all these cases
GIST belonged to either the very low, low or intermediate
risk classes.
In 3/25 (12%) cases, radical resection was not possible
due to diffuse disease (2 cases) or local infiltration (1
cases) and the final histopathology described the speci-
mens as malignant, high-risk GIST (Table 1). There was no
intra or postoperative mortality. In one case (5.2%) acci-
dental intraoperative spleen damage occurred that was
treated by splenorraphy.
Postoperative mortality rate was 32% (8/25). Four cases
died of wound infection, two of lung atelectasis, one of
pleural effusion and one of central venous catheter infec-
tion. The mean follow-up period was 54 ± 10 months
(range 22–120).
The 5 and 10-year overall actuarial survival using the Kap-
lan-Meier curve was 65% (standard error 21%) and 34%
respectively (standard error 13%) with a mean survival of
85 ± 16 months (Figure 1).
The mean survival was 126 ± 23 months for tumors <5
cm, 81 ± 16 for tumors 5–10 cm and 43 ± 12 for tumors
>10 cm (Figure 2). Difference between <5 cm and >10 cm
was statistically significant (p < 0.05; log rank test).
Mean actuarial survival after complete and incomplete
resection was 105 ± 19 versus 43 ± 12 months respectively
(Figure 3) and this difference was statistically significant
(p < 0.05, log rank test). High-risk tumors had a signifi-
cantly shorter survival than low and very low risk tumors
(mean 43 versus 144 months, p < 0.01). There was no sta-
tistically significant difference in survival by the location
of tumors.
Discussion
Gastrointestinal stromal tumors are rare neoplasm that
may arise virtually in any part of the gastrointestinal tract.
It has been recently proposed that GISTs may develop
from the interstitial cells of Cajal [1], since the same
immunohistochemical markers can identify GIST. Pres-
ence of CD34 antigen and the c-KIT proto-oncogene
(CD117) represent the histological features of these
tumors [1,3,8].
Other studies [1-3,8] also demonstrated the diagnostic
role of c-KIT expression, now considered a highly specific
marker for GISTs. c-KIT expression can also be used for
medical therapy [2], since new drugs, (STI-571 imatinib),
is characterized by a selective action on tyrosine kinase
receptors, and it has been recently used with good results
[6,12,13].
C-KIT always immunostains positively in GISTs, with very
rare exceptions, due to artifacts, sampling errors, lack of
kit caused by clonal evolution or mutations [2]. Further-
more c-KIT expression is extremely helpful to validate
diagnosis of GIST in case of extra-gastrointestinal localiza-
tion (omentum, mesentery, retroperitoneum or elsewhere
in the abdominal cavity) [2].
In our experience the stomach was the most common site
of GIST location, followed by small bowel and other loca-
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found in larger series [9].
Brennan et al, in 200 patients found no correlation
between tumor's site of origin and survival. Opposite
results have been reported by Lillemoe et al [10], in 133
resected GIST, where survival was, indeed in relationship
with tumors' site.
There are difficulties to classify benign or malignant GIST
using the standard criteria commonly used for other
tumors and most authors agree that tumors size and the
number of mitoses at HPF are the most important factors
related to prognosis [2,3,5]. These findings allowed
Fletcher et al [2], to propose a "risk of aggressive behavior"
classification of GIST considering only size and HPF
mitotic count (Table 1).
Surgical resection is still "the gold standard treatment" for
GISTs, allowing to reach a cumulative 3–5 years survival
of almost 50% and 35% respectively [1,3,4]; these find-
ings are confirmed by our series (Figure 1).
Our study confirms that size of the tumors as well as
mitotic count are highly related to the prognosis: patients
suffering from GISTs less than 5 cm in diameter have a sig-
nificantly longer survival than patients with bigger
tumors: 126 ± 23 months for tumor <5 cm, 81 ± 16 for 5–
10 cm and 43 ± 12 for >10 cm GIST (Chart 2) (p < 0.05).
Similar results have been reported by Brennan et al, [4] as
well as other authors [7].
Using the "risk of aggressive behavior classification"
(Table 1) [2] for our patients, we confirmed that low
number of mitosis at HPF are related to prognosis: we
found a significantly longer survival in very low and low
risk group compared with high risk group (p < 0.05).
In our experience macroscopically complete resection was
possible in 21/25 cases (84%) (Table 2); the presence of
residual tumor was significantly related to early recurrence
and short survival (Figure 3).
The negative effect of macroscopic residual tumor is well
known: Ott et al, [7] and Brennan et al, [4] found a signif-
icantly longer 5 year survival rate when GIST were com-
pletely removed (42% versus 9%).
We found no difference in term of survival considering
different tumor locations, but the prognostic significance
of the site of origins in term of survival is still controversy.
While Brennan et al's [4], finding are in keeping with ours,
results from the 164 patients treated at the Johns Hopkins
Hospital showed longer survival for esophageal and duo-
denal located GIST [10].
Since approximately 50% of the patients will not survive
more than 5 years even when complete resection is
achieved, several chemo-radiotherapeutic adjuvant regi-
mens have been proposed.
As these tumors mainly arise in gastrointestinal tract and
irradiation may produce severe damage on adjacent
organs, radiotherapy seems to be indicated only to pre-
vent local recurrence in selected cases of rectal GISTs
[7,11].
A combined European/Australian study [2,12] has been
started, in order to test the effectiveness of a new chemo-
therapy regimen based on imatinib mesylate STI-571: a
tyrosine kinase receptors inhibitor [6], highly selective on
GISTs and able to perform a "target" therapy, based on the
c-KIT expression (CD117) of these tumors. Preliminary
results of the first phase trials demonstrated up to 80% of
partial response in patients suffering from metastatic or
recurrent GISTs treated by imatinib.
Similar results have been obtained in a phase II and III
study, started in the United States, on unresectable or met-
astatic GISTs [2,13].
An adjuvant or palliative therapy by oral administration
of imatinib is now considered mandatory for unresectable
or metastatic diseases as suggested by a recent and exten-
sive review by Bucher et al [14], while its role in poten-
tially resectable GITS or as neo-adjuvant regimes has to be
demonstrated yet.
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Our experience confirms that GISTs are uncommon and
aggressive cancers. The prognosis is strictly related to size
and number of mitosis at HPF. Complete surgical resec-
tion of the tumors still remains the only chance of long
term survival for these patients. Imatinib therapy should
be used for patients not suitable for surgery due to poor
general condition or once a complete resection it is not
technically possible. Its role in adjuvant settings after
complete excision is still controversial.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
LB: performed the literature review and contribute to
manuscript writing
AB: supervised the manuscript preparation
GD: helped during the manuscript preparation (introduc-
tion and discussion) and literature review
FR: helped during the manuscript preparation especially
in the statistical methods and discussion
RD: helped during the manuscript preparation and final
revision, performed most of the surgical procedure
References
1. Trupiano J, Stewart R, Misick C, Appleman H, Goldblum J: Gastric
stromal tumors, a clinicopathological study of 77 cases with
correlation of features with nonaggressive and aggressive
clinical behaviour.  Am J Surg Path 2002, 26:705-714.
2. Fletcher C, Berman J, Corless C, Gorstein F, Lasota J, Longley BJ,
Miettinen M, O'Learly TJ, Remotti H, Rubin BP, Shmookler B, Sobin
LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors:
a consensus approach.  Hum Pathol 2002, 33:478-483.
3. Miettinen M, El-Rifai W, Sobin LH, Lasota J: Evaluation of malig-
nancy and prognosis of gastrointestinal stromal tumors: a
review.  Hum Pathol 2002, 33:459-465.
4. DeMatteo R, Lewis JJ, Leung D, Mudan S, Woodruff J, Brennan MF:
Two hundred gastrointestinal stromal tumors: recurrence
patterns and prognostic factors for survival.  Ann Surg 2000,
231:51-64.
5. Bilimoria M, Holtz DJ, Mirza NQ, Feig BW, Pisters PW, Patel S, Pol-
lock RE, Benjamin RS, Papadopoulos NE, Plager C, Murphy A, Griffin
JR, Burgess MA, Hunt KK: Tumor volume as a prognostic factor
for sarcomatosis.  Cancer 2002, 94:2441-2446.
6. Shawer LK, Slamon D, Ullrich A: Smart drugs: tyrosine kinase
inhibitors in cancer therapy.  Cancer Cell 2002, 1:117-123.
7. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ:
The effect of surgery and grade on outcome of gastrointesti-
nal stromal tumors.  Arch Surg 2001, 136:383-389.
8. Di Matteo G, Pescarmona E, Peparini M, DiMatteo FM, Zeri KP, Mas-
cagni D, Mele R, Maturo A, Redler A, DeAntoni E: Histopathologi-
cal features and clinical course of the gastrointestinal
stromal tumors.  Hepatogastroenterol 2002, 49:1013-1016.
9. Skandalakis JE, Gray SW: Smooth muscle tumors of the alimen-
tary tract. In: Progress in clinical cancer.  Grune & Stratton,
New York; 1965:692-708. 
10. Lillemoe KD, Efron DT: Gastrointestinal stromal tumors. In
Current surgical therapy.  Edited by: Cameron JL, Gery L. Mosby
Inc, USA; 2001:112-117. 
11. Shiu MH, Farr GH, Hagdu SI: Myosarcomas of the stomach: nat-
ural history, prognostic factors and management.  Cancer
1982, 49:177-187.
12. van Oosterom AT, Judson I, Verweij J, Stroobants S, Di Paola ED,
Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silber-
man S, Nielsen OS: Safety and efficacy of imatinib (STI-571) in
metastatic gastrointestinal stromal tumors: A phase I study.
Lancet 2001, 358:1421-1423.
13. Joensuu H, Roberts PJ, Salomo-Rikala M, Andersson LC, Tervahartiala
P, Tuveson D, Silbeman SL, Capdeville R, Dimitrijevic S, Druker B,
Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in
a patient with a metastatic gastrointestinal stromal tumor.
N Engl J Med 2001, 344:1052-1056.
14. Bucher P, Villiger P, Egger JF, Buhler LH, Morel P: Management of
gastrointestinal stromal tumours: from diagnosis to treat-
ment.  Swiss Med Wkly 2004, 134:145-153.Page 5 of 5
(page number not for citation purposes)
